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Abstract
 
Tumor necrosis factor (TNF) is a potent cytokine exerting critical functions in the activation
and regulation of immune and inflammatory responses. Due to its pleiotropic activities, the
amplitude and duration of TNF function must be tightly regulated. One of the mechanisms
that may have evolved to modulate TNF function is the proteolytic cleavage of its cell surface
receptors. In humans, mutations affecting shedding of the p55TNF receptor (R) have been
linked with the development of the TNFR-associated periodic syndromes, disorders character-
ized by recurrent fever attacks and localized inflammation. Here we show that knock-in mice
expressing a mutated nonsheddable p55TNFR develop Toll-like receptor–dependent innate
immune hyperreactivity, which renders their immune system more efficient at controlling
intracellular bacterial infections. Notably, gain of function for antibacterial host defenses ensues
at the cost of disbalanced inflammatory reactions that lead to pathology. Mutant mice exhibit
spontaneous hepatitis, enhanced susceptibility to endotoxic shock, exacerbated TNF-dependent
arthritis, and experimental autoimmune encephalomyelitis. These results introduce a new concept
for receptor shedding as a mechanism setting up thresholds of cytokine function to balance
resistance and susceptibility to disease. Assessment of p55TNFR shedding may thus be of prog-
nostic value in infectious, inflammatory, and autoimmune diseases.
Key words: TRAPS • arthritis • EAE • chronic hepatitis • LPS toxicity
 
Introduction
 
TNF is a potent cytokine exerting critical beneficial activities
in immune regulation and host defense, as well as hazardous
proinflammatory and cytotoxic functions. TNF mediates
its pleiotropic activities via two cell surface receptors,
p55TNFR (TNFRI, CD120a) and p75TNFR (TNFRII,
CD120b). The two TNFRs are ubiquitously expressed and
display structurally similar extracellular domains but signal
through distinct intracellular regions, with p55TNFR con-
taining a death domain that is not present in the p75TNFR
(1). Signaling through the p55TNFR leads to the activation
of the I
 
 
 
B kinase complex and mitogen-activated protein
kinase  pathways,  and to the initiation of apoptotic cell
death (for review see references 2 and 3). Previous studies
in p55TNFR-deficient mice established the requirement of
this receptor in the organization of secondary lymphoid organ
structure and function (4), in host defense against various
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microorganisms (3, 5–8), in the induction and maintenance
of various chronic inflammatory pathologies (9), and the
toxicity of TNF during endotoxic shock (10–12).
TNFRs are initially synthesized as membrane-anchored
proteins, which can subsequently be released from the cell
surface by proteolysis, forming soluble molecules capable of
binding the TNF ligand. Soluble TNFRs are constitutively
released in the circulation (13), and their levels increase in
the course of various disease states (14) and after TNF stim-
ulation (15, 16). In cell culture systems, soluble receptors
are rapidly produced in response to various stimuli such as
TNF (17), LPS (18), PMA, and IL-10, or after T cell (19)
and neutrophil activation (20). Shedding and the resultant
acute decrease in the number of receptor molecules on the
cell surface may serve to transiently desensitize cells to the
TNF action. In addition, the pool of soluble forms pro-
duced could function as physiological attenuators of the
TNF activity, competing for the ligand with the cell sur-
face receptors. Moreover, it has been proposed that soluble
receptors can stabilize and preserve circulating soluble TNF
and thus function as TNF agonists (21).
Up until now, a variety of approaches have been used to
determine the biological functions of membrane-bound
p55TNFR. These include experiments using receptor-spe-
cific antibodies (22), receptor-specific ligands (23), and
p55TNFR-deficient mice (10–12). However, the biologi-
cal significance of p55TNFR shedding has remained un-
clear. In humans, impaired p55TNFR clearance from the
cell surface has recently been proposed as a novel mecha-
nism of disease. Mutations on the human p55TNFR gene
causing reduced levels of shedding were proposed to be re-
sponsible for a newly defined class of autoinflammatory dis-
eases, termed TNFR1-associated periodic syndromes (TRAPS;
reference 24).
To investigate the in vivo role of p55TNFR shedding,
we have used a knock-in approach to generate mutant mice
expressing nonsheddable p55TNFRs. We show here that
similarly to the TRAPS syndrome in humans, defective
shedding of the p55TNFR in mice leads to a persistent ex-
pression of the receptor on the cell surface and acts as a
dominant genetic trait to provoke spontaneous autoinflam-
matory reactions. We further show that defective p55TNFR
shedding causes innate immune hyperresponsiveness, result-
ing in enhanced host defenses to bacterial infections as well
as to the sensitization of the host to the in vivo toxicity of
TNF and LPS. Notably, defective TNFR shedding leads to
exacerbated clinical outcomes in mouse models of inflam-
matory diseases, demonstrating the significance of receptor
shedding in setting up thresholds of TNF function and bal-
ancing resistance and susceptibility to disease.
 
Materials and Methods
 
Generation of p55
 
 
 
NS 
 
Mice.
 
A mutation deleting 15 nucleotides
encoding for amino acids 202–206 was introduced in exon 6 of
the mp55TNFR gene by PCR mutagenesis on a 2-kb Sma/
HindIII subcloned genomic fragment containing exons 6 and 7
(36). For the targeting vector, a 4.6-kb XbaI/SmaI genomic frag-
ment was used as the left arm of homology and a 4-kb Sma/
HindIII genomic fragment containing the 
 
p55
 
 
 
NS 
 
mutation was
used as the right homology arm. A loxP-flanked neo selection cas-
sette (L2neo) was introduced into an SmaI site in intron 5 of the
p55TNFR gene between the two arms of homology and a PGK-
tk
 
  
 
selection marker was introduced at the 3
 
  
 
of the targeting vec-
tor. The targeting vector was linearized by NotI before electropo-
ration into CCE mouse embryonic stem cells derived from 129Sv
mice (37). Transfection, selection, expansion, and screening of re-
combinant clones, and generation of germline-transmitting chi-
meras was performed as described previously (28). For the exci-
sion of the loxP-flanked neo selection cassette, fertilized oocytes
from mice carrying the targeted neo-containing 
 
p55
 
 
 
NS 
 
gene were
used to introduce the pMC-Cre circular plasmid vector using pro-
nuclear DNA microinjection. Pups born from these oocytes were
tested and shown to have excised the loxP-flanked neo cassette.
Genotyping was performed by Southern blot using the SmaI-
BamHI probe shown in Fig. 1 A. PCR genotyping was per-
formed with the following primers: 5
 
 
 
-GTGTATGAAGTTGT-
GCCTACC-3
 
  
 
and 5
 
 
 
-CTCAGCCTAGAGTCCTTAACC-3
 
 
 
,
producing fragments of 425 and 410 bp for the wild-type and the
mutant allele, respectively.
 
Mice. p55
 
 
 
NS 
 
mice were maintained on a C57BL/6 
 
  
 
129Sv
genetic background (referred to as B6,129), or backcrossed to
C57BL/6 mice for at least five generations. Strains deficient in
TNF (28), RAG-1 (The Jackson Laboratory; reference 38),
p55TNFR (10), p75TNFR (39), and 
 
lpr/lpr
 
 (The Jackson Labo-
ratory) were maintained on a mixed C57BL/6 
 
  
 
129Sv genetic
background. Tg197 mice (30) were maintained on a CBA 
 
 
 
C57BL/6 background. All mice were kept under specific patho-
gen-free conditions.
 
Use of Mouse Embryonic Fibroblasts (MEFs) to Assess Signaling
through p55
 
 
 
NS 
 
Receptor.
 
MEFs (2 
 
  
 
10
 
6 
 
cells) from wild-type
and 
 
p55
 
 
 
NS/
 
 
 
NS 
 
mice were cultured in DMEM (GIBCO BRL)
supplemented with 10% heat-inactivated FCS (GIBCO BRL), 2
mM 
 
l
 
-glutamine, 100 U/ml penicillin, and 100 
 
 
 
g/ml strepto-
mycin, and were either left untreated or stimulated with 100 ng/
ml human TNF (Genentech, Inc.). Whole cell lysates were har-
vested with a lysis buffer containing 1% Igepal CA-630 (Sigma-
Aldrich) and the proteins were separated in 12% SDS-polyacryl-
amide gels and blotted onto nitrocellulose membrane. The
following antibodies were used: phospho-specific I
 
 
 
B
 
  
 
mono-
clonal antibody (catalog no. 9246; Cell Signaling Technology)
and rabbit anti-peptide antibody directed against I
 
 
 
B
 
  
 
(catalog
no. sc-371; Santa Cruz Biotechnology, Inc.).
 
Flow Cytometry.
 
Peritoneal exudate cells were adjusted to 2 
 
 
 
10
 
6 
 
cells/ml in DMEM (GIBCO BRL) supplemented as described
above and stimulated with 100 ng/ml PMA (Sigma-Aldrich) or
left untreated for 20 min at 37
 
 
 
C, 5% CO
 
2
 
. Cells were then
washed and incubated with primary monoclonal rat anti-mup55
TNFR IgG antibody (provided by W. Buurman, University of
Limburg, Diepenbeek, Netherlands) and secondary goat anti–rat
IgG FITC (catalog no. 3052-02; Southern Biotechnology Associ-
ates, Inc.) for 30 min at 4
 
 
 
C, and analyzed by flow cytometry.
 
ELISA from Murine p55TNFR, p75TNFR, and TNF.
 
Se-
rum was collected via tail vein exsanguinations before or 30, 90,
and 180 min after intraperitoneal injection of 100 
 
 
 
g LPS (
 
Salmo-
nella enteritidis
 
, L-6011; Sigma-Aldrich) and assayed using specific
ELISA assays (based on the same anti-mup55 TNFR antibody
used for flow cytometry as above; provided by W. Buurman) as
described previously (28).
 
Histopathology.
 
Tissues from freshly dissected mice were im-
mersion fixed overnight in neutral buffered formalin and embedded 
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in paraplast (BDH Laboratory Supplies). Sections were cut and
stained with hematoxylin and eosin according to standard procedure,
dehydrated, and mounted in DPX (BDH Laboratory Supplies).
 
Immunohistochemistry.
 
Mice were perfused via the aorta with
4% paraformaldehyde in 0.1 M phosphate buffer. Brains and spi-
nal cords were removed and immersed in the same fixative for
12–24 h. Tissue blocks were routinely embedded in paraffin.
5-
 
 
 
m thick sections were stained with hematoxylin/eosin to vi-
sualize infiltrated inflammatory cells and with luxol fast blue for
myelin. Immunocytochemistry was performed with a biotin/avi-
din technique with primary antibodies against T cells (CD3;
Seralab) and activated macrophages/microglia (Mac-3; Serotec).
An average inflammatory index was created by counting the
number of inflamed blood vessels in 10–15 spinal cord cross sec-
tions and subsequent division by the number of cross sections.
 
TNF and LPS Administration and Listeria Infection.
 
Recombi-
nant human TNF (Genentech, Inc.) was administered intrave-
nously at 60 
 
 
 
g/mouse and LPS (
 
S. enteritidis
 
, L-6011; Sigma-
Aldrich) was administered intraperitoneally at the indicated doses.
Enbrel (etanercept; Immunex) was administered intraperitoneally
1 h before LPS administration. 
 
Listeria monocytogenes
 
 strain L028
(40) was administered intraperitoneally at the indicated doses.
Survival was monitored for 10 d in all cases.
 
Northern Blot Analysis of Macrophage RNA.
 
10 
 
 
 
g total RNA,
isolated as described previously (28), was resolved in 1.2% form-
aldehyde agarose gel, blotted onto Hybond N
 
  
 
nylon membrane
(Amersham Biosciences), and hybridized with a 0.45-kb
 
32
 
P-labeled NarI-BglII genomic probe containing part of the first
exon of the muTNF gene. Membranes were stripped and rehy-
bridized with a 
 
  
 
actin probe.
 
Measurement of Nitric Oxide (NO).
 
NO was measured in
culture supernatants of thioglycollate-elicited peritoneal mac-
rophages. Macrophages were isolated from wild-type and
 
p55
 
 
 
NS/
 
 
 
NS 
 
mice (
 
n 
 
  
 
2–3 per group), cultured in flat-bottomed
96-well plates at a density of 5 
 
  
 
10
 
5
 
/well in DMEM (GIBCO
BRL), supplemented as described above, and either left untreated
or stimulated with 0.1, 1, 2, and 5 
 
 
 
g/ml LPS (
 
S. enteritidis
 
,
L-6011; Sigma-Aldrich), or 1, 10, 50, and 100 
 
 
 
g/ml polyi-
nosinic-polycytidylic acid (poly IC; Amersham Biosciences). Su-
pernatants were collected 24 h later, and the presence of NO was
determined by measuring the amount of nitrite, a metabolic prod-
uct of NO (41).
 
Immunizations and Experimental Autoimmune Encephalomyelitis
(EAE) Induction.
 
T cell priming was assayed in popliteal LN
cells isolated from 7–11-wk-old mice 9 d after footpad immuni-
zation with 150 
 
 
 
g rat myelin oligodendrocyte glycoprotein
(MOG) peptide (MOGp35-55, MEVGWYRSPFSRVVH-
LYRNGK; Sigma-Genosys) in CFA containing a total of 1 mg
H37Ra (Difco Laboratories) per mouse. EAE was induced in 10–
12-wk-old male mice after tail-base immunization with 150 
 
 
 
g
rat MOG peptide in CFA containing a total of 1 mg H37Ra per
mouse. At the time of immunization and 48 h later, mice re-
ceived 40 ng of pertussis toxin (PTx; Sigma-Aldrich) intraperito-
neally. Clinical signs of disease were scored on a scale of 0–5 as
follows: 0, no disease; 1, tail paralysis; 2, hind limb weakness; 3,
hind limb paralysis; 4, hind limb plus forelimb paralysis; 5, mori-
bund or dead animals. T cell “memory” was assayed in spleen
cells of mice 20 d after induction of EAE. For histological evi-
dence of EAE, brains and spinal cords were removed.
 
T Cell Proliferation Assay.
 
T cell proliferative responses were
assessed at indicated time points in total LN or spleen cells. After
erythrocyte lysis, cells were cultured in flat-bottomed 96-well
plates at a density of 7 
 
  
 
10
 
5 
 
per well. Cultured medium consisted
Figure 1. Generation and initial characterization of p55 NS mice.
(A) Schematic representation of the murine p55TNFR genomic locus
(top), the p55 neo targeted locus generated by homologous recombina-
tion in embryonic stem cells (middle), and the p55 NS locus generated
after Cre-mediated excision of the loxP-flanked neo cassette (bottom).
Exons are indicated as closed boxes with open boxes representing 5  and
3  untranslated regions. The p55 NS mutation that deletes amino acids
202–206 in the mature protein is indicated. The white arrow shows the
transcriptional orientation of the neo cassette and arrowheads indicate
loxP sites. B and S indicate BamHI and SmaI restriction enzyme sites,
respectively. (B) Southern blot analysis of BamHI-digested tail DNA
from mice with the indicated genotypes using the SmaI-BamHI probe.
(C) PCR analysis of tail DNA from mice with the indicated genotypes
using PCR primers (small arrows in A) that amplify fragments of 425
and 410 bp for the wild-type and the mutant alleles, respectively. (D) Cell
surface p55TNFR levels on peritoneal exudate cells from p55TNFR-
deficient (black), wild-type (red), and homozygous p55 NS/ NS mice
(blue) analyzed for mp55TNFR expression before or after PMA activa-
tion. Data are representative of two independent experiments. (E) ELISA
analysis of soluble p55TNFR levels in sera from mice with the indicated
genotypes before and after LPS stimulation. Data are representative of
three independent experiments. (*, P   0.05). (F) Western blot analysis
of I B  phosphorylation and degradation in wild-type (wt) and ho-
mozygous p55 NS/ NS ( NS) MEFs stimulated with human TNF and
harvested at the indicated time points. All mice were in a B6,129 ge-
netic background. White lines indicate that intervening lanes have been
spliced out. 
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of DMEM (GIBCO BRL) supplemented with 5% heat-inacti-
vated FCS, 
 
l
 
-glutamine, and antibiotics. Triplicate cultures were
incubated at 37
 
 
 
C in the presence or absence of indicated concen-
trations of rat MOG peptide. After 52 h, cultures were pulsed
with 1 
 
 
 
Ci [methyl-
 
3
 
H]TdR (Amersham Biosciences) for 18 h.
Cells were harvested on glass fiber filters and incorporation of
[methyl-
 
3
 
H]TdR was measured by liquid scintillation counting.
 
Results
 
Generation and Initial Characterization of p55TNFR
Nonsheddable (p55
 
 
 
NS
 
) Mice.
 
To investigate the biological
function of p55TNFR shedding, we generated p55TNFR
nonsheddable mutant mice (referred to as p55
 
 
 
NS
 
) using
gene targeting by homologous recombination in embry-
onic stem cells (Fig. 1, A–C). To examine the expression
levels and assess the shedding of the mutant p55TNFR
from the cell surface, we analyzed freshly isolated perito-
neal exudate cells by flow cytometry using an antibody spe-
cific for the murine p55TNFR. Cells were analyzed before
and 20 min after treatment with PMA, an agent widely
used to induce proteolytic cleavage of several cell surface
proteins including p55TNFR (25). Before treatment, the
expression levels of the mutant receptor in 
 
p55
 
 
 
NS/
 
 
 
NS 
 
cells
were similar to those in control cells, indicating that the
 
p55
 
 
 
NS 
 
mutation does not interfere with the correct regula-
tion of p55TNFR expression. However, p55TNFR levels
persisted in 
 
p55
 
 
 
NS/
 
 
 
NS 
 
cells after activation with PMA, in
contrast to wild-type cells where the receptors were com-
pletely cleared from the cell surface (Fig. 1 D), indicating
that the 
 
p55
 
 
 
NS mutation abolishes receptor shedding. De-
fective shedding of the mutated receptor was also con-
firmed by the complete absence of soluble p55TNFR pro-
tein in sera from LPS-stimulated p55 NS/ NS mice (Fig. 1
E). Interestingly, the levels of soluble p55TNFR in sera
from heterozygous p55 NS/  mice were as low as 15% of
wild-type levels, significantly lower than those in p55 / 
mice ( 40% of wild-type), suggesting that the p55 NS mu-
tation functions in a dominant fashion to also suppress
shedding of the wild-type protein. Taken together, these
results show that in resting cells, the cell surface expression
of the mutant p55 NS protein is correctly regulated and that
after appropriate stimulation, inability to shed the mutant
receptor leads to its persistent expression on the cell surface.
To address whether the nonsheddable mutant receptor
remains functional and to investigate possible alterations in
its signaling capacity, we analyzed the activation of the nu-
clear factor  B signaling pathway, which occurs within a
few minutes after p55TNFR stimulation. MEFs from wild-
type and p55 NS/ NS mutant mice were treated with recom-
binant human TNF, which is known to signal exclusively
through the mouse p55TNFR (26), and I B  phosphory-
lation and degradation were measured by Western blot
analysis (Fig. 1 F). Rapid appearance of phosphorylated
I B   with concomitant I B   degradation occurs with
similar kinetics in mutant and control MEFs, indicating
that the p55 NS mutation does not influence the signaling
capacity of the mutant receptor. Because it is known that a
physiological function of the p55TNFR is to regulate the
correct structural organization of the spleen (27), to further
investigate the in vivo functionality of the p55 NS receptor,
we analyzed the splenic microarchitecture of p55 NS/ NS
mice. The spleens of p55 NS/ NS mice showed a normal mi-
croarchitecture and efficient germinal center formation
after immunization with the thymus-dependent antigen
sheep red blood cells (not depicted), suggesting that the
p55 NS mutation does not interfere with the physiological
function of the p55TNFR.
Spontaneous Development of Chronic Active Hepatitis in
p55 NS Mice. Impaired shedding of the p55TNFR is
thought to be responsible for recurrent attacks of general-
ized inflammation in human TRAPS patients. To examine
the potential development of spontaneous pathologies in
p55 NS mice, we performed histopathological evaluation of
tissue sections from several organs of both young and adult
homozygous and heterozygous animals. No obvious ab-
normalities could be observed in the lung, spleen, pancreas,
kidneys, and joints (not depicted). However, histopatho-
Figure 2. Active chronic hepatitis in p55 NS mice. Histologic examination
of liver sections from B6,129 p55 NS mice at 8 wk in different experimental
groups. (A and B) Focal inflammation in liver parenchyma characterized
by infiltration of lymphocytes and polymorphonuclear cells and by the
presence of apoptotic hepatocytes (inserts). Disease develops in homozygous
p55 NS/ NS (A) as well as in heterozygous p55 NS/  (B) mutant mice, albeit
with reduced severity. (C) Liver sections from p55 NS/ NS.TNF /  mice
present no signs of pathology. Inflammatory foci and presence of apop-
totic hepatocytes persist in the liver of p55 NS/ NS.RAG-1 /   (D),
p55 NS/ NS.lpr/lpr (E), or p55 NS/ NS.p75TNFR /  (F) double mutant
mice. Magnification, 40 and 400 for the insets.Xanthoulea et al. 371
logical analysis of the liver revealed the spontaneous develop-
ment of a mild form of active chronic hepatitis, characterized
by focal parenchymal inflammation with infiltration of lym-
phocytes, polymorphonuclear cells, and other leukocytes, and
by the presence of apoptotic hepatocytes in the majority of the
inflammatory foci. Liver pathology was already apparent at
3–4 wk of age, persisted throughout adulthood, and was most
profound in homozygous p55 NS/ NS mutant mice, which
showed larger and more numerous inflammatory foci in com-
parison to heterozygous p55 NS/  mice (Fig. 2, A and B).
Hepatitis developed with 100% phenotypic penetrance in
both homozygous and heterozygous mutant mice, whereas no
liver pathology could be detected in littermate controls.
To evaluate the molecular and cellular mechanisms of
this liver pathology, we generated a series of intercrosses
with strains of mice that are genetically deficient in the ex-
pression of TNF, RAG-1, Fas, or the p75TNFR. TNF
expression is essential for hepatitis development because
p55 NS/ NS.TNF /  mice do not show this phenotype (Fig.
2 C). Interestingly, T and B lymphocytes are not required
for the development of liver inflammation and the induc-
tion of hepatocyte apoptosis in this model, as shown by the
development of hepatic lesions including apoptotic hepato-
cytes in the T and B cell–deficient p55 NS/ NS.RAG-1 / 
mice (Fig. 2 D). Finally, histological examination of
liver sections from Fas-deficient p55 NS/ NS.lpr/lpr or
p75TNFR-deficient p55 NS/ NS.p75TNFR /  mice showed
that the liver pathology develops independently of the
function of Fas or the p75TNFR in this system (Fig. 2, E
and F). These results demonstrate that defective p55TNFR
shedding triggers the spontaneous development of a
chronic autoinflammatory reaction in the liver, which leads
to the establishment of a TNF-dependent, yet Fas- and T
cell–independent, chronic active hepatitis. Interestingly,
this phenotype also develops in heterozygous mutant ani-
mals, indicating that the p55 NS mutation acts in a domi-
nant fashion to induce liver inflammation.
Defective p55TNFR Shedding Increases Susceptibility of Mice
to the Systemic Toxicity of TNF and LPS. To examine the
potential involvement of p55TNFR shedding in TNF tox-
icity in vivo, we investigated the susceptibility of homozy-
gous p55 NS/ NS and heterozygous p55 NS/  mutant mice to
normally sublethal doses of exogenously administered re-
combinant human TNF, which can only bind to the mu-
rine p55TNFR (26). Intravenous administration of 60  g of
recombinant human TNF to normal mice resulted in the
death of 1 out of 9 mice (11% lethality). Notably, the same
dose of human TNF resulted in significantly increased le-
thality in both homozygous (100%) and heterozygous (71%)
p55 NS mice (Table I), suggesting that p55TNFR shedding
is important for protection from TNF toxicity in vivo.
Previous studies have shown that the function of the
TNF–p55TNFR system is not required for LPS toxicity,
suggesting that pathways different from TNF–p55TNFR
are critical in this model of endotoxic shock (10, 12, 28).
To address the involvement of p55TNFR shedding in LPS
toxicity, we measured the susceptibility of mutant mice to
normally sublethal doses of LPS. Administration of 340 or
300  g LPS (per 25 g of body weight) resulted in 37 and
0% lethality, respectively, in wild-type mice, but caused
significantly increased lethality (nearly 100%) in both ho-
mozygous and heterozygous p55 NS mutant mice (Table I).
Interestingly, anti-TNF treatment protected p55 NS/ NS mice
from LPS toxicity, demonstrating that the increased suscep-
tibility of these mice to LPS is absolutely dependent on
TNF function (Table I). These results demonstrate that
p55TNFR shedding plays a crucial role in the desensitiza-
tion of the host from the deleterious activities of TNF dur-
ing LPS-induced endotoxic shock.
Increased Resistance of p55 NS Mice to L. monocytogenes Infec-
tions. TNF–p55TNFR signaling plays a critical role in
antibacterial host defense and TNF- or p55TNFR-defi-
cient mice are highly susceptible to infection with the in-
Table I. Measurements of Human Recombinant TNF– or 
LPS-induced Lethality in p55 NS Mice
p55    p55 NS/ NS p55 NS/  p55 NS/ NS
(deaths/total) (deaths/total) (deaths/total) (deaths/total)
rhTNF 1/9 8/8a 5/7b —
(60  g/mouse) (11%) (100%) (71%)
LPS 7/19 17/18a 10/10a —
(340  g/25 g) (37%) (94%) (100%)
LPS 0/11 11/11 — 2/11c
(300  g/25 g) (0%) (100%) (18%)
C57BL/6 p55 NS/ NS, p55 NS/  littermates and age-matched C57BL/6
controls (8–12 wk of age) were injected with the indicated amounts of
human recombinant TNF (intravenously) or LPS (intraperitoneally; S.
enteritidis, L-6011; Sigma-Aldrich). Enbrel (etanercept; Immunex) was
administered intraperitoneally 1 h before LPS injections at a dose of 2 mg/
mouse. Survival was monitored for 10 d. P-values by Fisher’s exact test:
aP   0.004.
bP   0.04 (p55 NS/ NS or p55 NS/  vs. p55   ).
cP   0.0002 (p55 NS/ NS with Enbrel vs. p55 NS/ NS without Enbrel
administration).
Table II. Measurements of Lethality after 
L. monocytogenes Infections
CFU
p55   
(deaths/total)
p55 NS/ NS
(deaths/total)
108 15/15 10/15a
107 15/15 4/15b
106 5/15 0/15a
105 0/15 0/15
B6,129 p55 NS/ NS and age-matched B6,129 p55    mice (10–12 wk of
age) were infected intraperitoneally with the indicated doses of L.
monocytogenes and survival was monitored for 10 d. P values by Fisher’s
exact test:
aP   0.042.
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tracellular bacterium L. monocytogenes (10, 11, 28). To in-
vestigate the effect of impaired p55TNFR shedding in host
defense mechanisms, we measured the survival of p55 NS/ NS
and control mice after infection with different doses of Lis-
teria. p55 NS/ NS mice showed increased resistance to Listeria
infection and could tolerate 10-fold higher doses than con-
trol mice (Table II). These results show that impaired shed-
ding of the p55TNFR enables enhanced antibacterial host
defenses, suggesting that induction of p55TNFR shedding
might be a mechanism used by pathogenic bacteria to es-
cape a neutralizing immune response.
Absence of p55TNFR Shedding Leads to Increased Innate Re-
sponsiveness. Administration of LPS to mice induces a rapid
increase in circulating levels of TNF and soluble TNFRs
(29). We have followed the kinetics of the systemic release
of TNF and the soluble p75TNFR in p55 NS/ NS and con-
trol mice before and after LPS administration. Levels of both
soluble proteins before LPS stimulation were comparable in
mutant and control mice. After LPS stimulation, however,
the peak concentration of both TNF and p75TNFR were
found to be significantly enhanced in sera of mutant mice as
compared with control animals (Fig. 3 A).
Macrophages are central regulators of the inflammatory
response and when activated they are able to produce a va-
riety of effector molecules. Moreover, macrophages are
considered to constitute the most prominent source of
TNF production in vivo. To investigate whether macro-
phages expressing the nonsheddable p55TNFR show in-
creased expression of TNF, we isolated thioglycollate-elic-
ited peritoneal macrophages from p55 NS/ NS and wild-type
mice, and we compared the kinetics and the levels of TNF
mRNA production after LPS induction using Northern
analysis. TNF mRNA was expressed at a low level in rest-
ing macrophages of both types of mice. After LPS induc-
tion, mRNA levels in wild-type macrophages rapidly
increase to a peak at 1 h and slowly return to baseline
between 3 and 6 h. Although p55 NS/ NS macrophages
showed similar kinetics of TNF mRNA production as
wild-type cells, they displayed substantially increased levels
of TNF mRNA at all time points measured. At 1 or 3 h af-
ter LPS induction, we could measure a 1.5–2-fold in-
creased production of TNF mRNA in p55 NS/ NS cells.
Moreover, at 6 h after LPS induction, TNF mRNA levels
in wild-type macrophages had returned to baseline but
were readily detectable and at a fivefold higher level in
p55 NS macrophages (Fig. 3 B). These data show that per-
sistent expression of cell surface p55TNFR results in in-
creased TNF mRNA accumulation upon LPS stimulation,
indicating the presence of a positive feedback loop operat-
ing between cell surface p55TNFR and TNF mRNA
transcription and/or stabilization. Apparently, induced
shedding of the receptor seems to be important for the dis-
ruption of this positive regulatory loop and the negative
regulation of TNF production.
To further validate the innate immune hyperresponsive-
ness of stimulated p55 NS/ NS macrophages, we have deter-
mined their capacity to release NO. Thioglycollate-elicited
peritoneal macrophages were stimulated in vitro with dif-
ferent doses of LPS or poly IC. Macrophages from p55 NS/ NS
mice responded to these innate immune activators with
1.5–3-fold higher NO production than normal macro-
phages (Fig. 3 C). Taken together, these results show
that after innate immune stimulation, defective p55TNFR
shedding promotes immune hyperresponsiveness, charac-
terized by enhanced and sustained production of innate ef-
fectors such as TNF or NO.
Increased Susceptibility of p55 NS Mice to Chronic Arthritis
and EAE. To address the potential impact of impaired
p55TNFR shedding on inflammatory disease induction
and progression, we have examined the responses of
p55 NS mice in two models of human disease. First, p55 NS
mice were crossed to transgenic mice expressing a 3  mod-
ified human TNF transgene (Tg197 line) and developing
a TNF-dependent chronic inflammatory polyarthritis
that  resembles human rheumatoid arthritis (30). Histo-
logical examination of joint sections from 4-wk-old
Figure 3. Innate immune hyperresponsiveness in p55 NS mice. (A) ELISA
analysis of soluble TNF and p75TNFR levels in sera of wild-type (p55 / )
and homozygous p55 NS/ NS mice (n   3 per group) before and after in-
traperitoneal injection of LPS. Data are representative of three independent
experiments. (B) Northern blot analysis of TNF mRNA in thioglycollate-
elicited peritoneal macrophages obtained from wild-type (p55 / ) and
p55 NS/ NS mice before or after stimulation with LPS. The membrane was
stripped and rehybridized with a   actin probe. (C) NO production in
culture supernatants of wild-type (p55 / ) and p55 NS/ NS thioglycollate-
elicited peritoneal macrophages in response to poly IC or LPS stimulation.
All mice were in a B6,129 genetic background. Data are representative of
three independent experiments.Xanthoulea et al. 373
Tg197.p55 NS/ NS  and Tg197.p55 /   littermate controls
revealed accelerated development of arthritis in mice carry-
ing the p55 NS mutation. All histological features of the dis-
ease, including hyperplasia of the synovial membrane and
polymorphonuclear and lymphocytic inflammatory infil-
trates of the synovial space, were much more profound in
joints from Tg197.p55 NS/ NS mice in comparison to con-
trols. Moreover, histological characteristics such as pannus
formation, articular cartilage destruction, and bone erosion
that appear only in the advanced stages of disease in 7–8-
wk-old Tg197.p55 /  mice, were already evident in joints
of 4-wk-old Tg197.p55 NS/ NS mice (Fig. 4, A and B).
Next, we assessed the susceptibility of p55 NS mice to the
development of EAE, a widely used model of human mul-
tiple sclerosis. EAE was induced by immunization with a
MOG peptide and by PTx coadministration, and disease
was monitored by both clinical examination and histo-
pathological analysis. Using an immunization protocol with
a low dose of PTx (40 ng), mild disease develops in  40%
of control mice. In contrast, p55 NS/ NS mice develop
disease with an almost 100% incidence (18 out of 19
p55 NS/ NS mice vs. 8 out of 19 p55 /  controls; P   0.001
by Fisher’s exact test) and with significantly increased se-
verity in comparison to controls (Fig. 5 A). Neuropatho-
logical evaluation was performed on a limited number (two
per experimental group) of animals on day 20 after induc-
tion of EAE. Inflammatory indices, measured in 10–15
cross sections of the spinal cord and a parameter for the de-
gree of inflammation, were higher in the p55 NS animals
than in the wild-type animals (p55 NS/ NS: 2.4 and 4.5 vs.
wild-type: 0.6 and 2.3). Demyelination in all animals was
very limited being  5% of the spinal cord white matter.
Immunohistochemistry revealed higher numbers of inflam-
matory T cells and activated macrophages/microglia in spinal
cord sections of p55 NS/ NS mice compared with normal
mice (Fig. 5 B). These results verify the clinical differences
observed between p55 NS/ NS and wild-type controls.
To determine whether the absence of p55TNFR shed-
ding could alter T cell responsiveness to MOG peptide,
thus explaining the observed differential susceptibility to
EAE, mice were immunized with the MOG p35–55 pep-
Figure 4. Increased susceptibility of p55 NS mice to chronic arthritis.
Histologic examination of ankle joints from Tg197.p55 /   (A) and
Tg197.p55 NS/ NS (B) littermates at 4 wk of age. Increased formation of
the inflammatory pannus and areas of cartilage and bone erosion are evi-
dent in B, whereas mild hyperplasia of the synovial membrane and onset
of infiltration of polymorphonuclear and lymphocytic inflammatory cells
in the synovial space is seen in A. All mice were littermates in a mixed
CBA,B6,129 background.
tide, and then analyzed for peptide-induced T cell prolifer-
ation. Both T cell priming (examined 9 d after immuniza-
tion) and MOG-specific memory responses (examined 20 d
after immunization) were comparable between p55 NS/ NS
and control mice (Fig. 5 C).
Taken together, these results show that persistent expres-
sion of a nonsheddable p55TNFR on the cell surface low-
ers the thresholds for the induction of chronic inflamma-
tory disease and results in exacerbated clinical outcome.
Discussion
TNF activity is controlled by multiple regulatory mecha-
nisms that maintain a balance between beneficial effects in
immune regulation and host defense, and potentially haz-
ardous cytotoxic and proinflammatory functions. The acti-
vation-induced shedding of the TNFRs is thought to pro-
vide a means for the regulation of TNF activity; however,
the in vivo role and significance of receptor shedding has re-
mained unclear. In humans, different missense mutations on
the p55TNFR gene that associate with impaired receptor
shedding are linked to a group of dominantly inherited au-
toinflammatory syndromes named TRAPS (24). To date,
 30 different mutations have been linked to TRAPS, the
majority of which represent single amino acid substitutions
in the first two cysteine-rich domains of the extracellular
part of the receptor (31). More recently, a novel TRAPS-
associated mutation has been reported that substitutes iso-
leucine 199, an amino acid located within the core of the
p55TNFR cleavage site (32). Characteristic clinical features
of TRAPS include recurrent episodes of fever, myalgia,
rash, abdominal pain, arthritis, and conjunctivitis, which are
thought to be primarily caused by a dysregulation of the
innate immune system in these patients. Some of the
p55TNFR mutations associated with TRAPS do not affect
shedding, suggesting that alternative mechanisms may con-
tribute to disease pathogenesis in these patients (33).
Here we investigate in vivo the physiological role of
p55TNFR shedding by using a knock-in approach to
generate mice expressing nonsheddable p55TNFR. The
p55 NS mutation does not affect the functionality of the
receptor, but completely abolishes both constitutive and
stimulation-induced proteolytic shedding, resulting in the
persistent expression of the p55TNFR on the cell surface.
Interestingly, heterozygous expression of the mutant recep-
tor results in strong reduction of soluble p55TNFR release
upon LPS stimulation, suggesting that the p55 NS mutation
has a dominant effect, reproducing the dominant nature of
the TRAPS mutations in humans. Although the specific
mechanism of this dominant interference of the nonshedd-
able receptor is still unclear, it might be hypothesized that
defective shedding might be due to the formation of non-
cleavable heterooligomers consisting of wild-type and mu-
tant receptors (34). Alternatively, if proteolytic shedding
plays a role in the physiological turnover and regulation of
the number of p55TNFR molecules present on the cell
surface, the nonsheddable receptors may preferentially ac-Role of TNFR Shedding in Pathophysiology 374
cumulate on the surface of heterozygous cells and cause the
dominant effect observed.
We show that interference with p55TNFR shedding in
mice leads to the development of a spontaneous autoin-
flammatory reaction manifesting as a mild form of active
chronic hepatitis involving local polymorphonuclear cell
activation and hepatocyte apoptosis. This pathology devel-
ops in both homozygous and heterozygous mutant mice,
indicating yet again the dominant nature of the mutation.
With reference to potential similarities of the p55 NS mice
to human TRAPS, it is worth noting that amyloidosis that
is occasionally observed in the human patients might be ex-
plained by such chronic TNF-dependent mild liver pa-
thology. Notably, anti-TNF (etanercept) administration to
TRAPS patients results in dramatic improvement in both
clinical and laboratory parameters, and decreases the sever-
ity, duration, and frequency of inflammatory symptoms
(35). Genetic elimination of TNF expression prevents the
development of the liver phenotype in p55 NS mice, dem-
onstrating that TNF-induced p55TNFR signaling is critical
for disease pathogenesis in this model, similarly to human
TRAPS patients. In addition, these liver lesions develop in
the absence of FasL expression, showing that Fas/FasL sig-
naling does not play an essential role for disease pathogene-
sis in p55 NS mice. Furthermore, the hepatic lesions de-
velop with similar severity in mice lacking both B and T
lymphocytes, suggesting that antigen-specific immune re-
sponses are not required for the liver pathology in this
model. Therefore, it seems that the liver lesions in p55 NS
mice are caused by an autoinflammatory reaction driven by
the innate immune system.
Our results show that inability to shed the p55TNFR
from the cell surface results in enhanced macrophage acti-
vation and increased release of effector molecules in re-
sponse to stimulation of Toll-like receptor 4 and Toll-like
receptor 3 using LPS and double stranded RNA, respec-
tively. This hyperactivity can be explained at least in part
by the finding that macrophages expressing nonsheddable
p55TNFR express increased levels of TNF in response to
LPS, suggesting that TNF expression is augmented through
a positive regulatory loop requiring the presence of surface
p55TNFR. The presence of significantly increased levels of
TNF in the serum of LPS-injected p55 NS mice compared
with controls also shows that in vivo, TNF accumulates at
higher levels in the absence of p55TNFR shedding. There-
fore, it seems that the defective shedding of p55TNFR po-
tentiates TNF function in the p55 NS mice.
We further show that both the beneficial and the hazard-
ous effects of TNF are exacerbated in mice expressing non-
sheddable  p55TNFR.  p55 NS mice show increased resis-
tance to infection with L. monocytogenes, demonstrating that
lack of p55TNFR shedding potentiates antibacterial host
Figure 5. Increased susceptibility of p55 NS mice to EAE. (A) EAE was
induced in C57BL/6 p55 NS/ NS and age-matched C57BL/6 controls
(10–12 wk of age; n   6 per group), by MOG p35–55 immunization as
described in Materials and Methods. Data presented are means   SEM of
disease scores. *, P   0.05 as determined by Student’s t test. Data are rep-
resentative of four separate experiments. (B) Immunohistochemistry from
C57BL/6 controls (a, c, and e) and C57BL/6 p55 NS/ NS (b, d, and f)
mice. In both cases the animals with the highest inflammatory index and
clinical signs were taken. (a and b) CD3 staining in spinal cord sections
showing lymphocyte infiltration. Inflammation in the p55 NS/ NS mouse
is more prominent (magnification, 37). Higher magnifications (80) of
panels a and b are shown in panels c and d, respectively. In addition to
higher numbers of inflammatory T cells, the p55 NS/ NS mouse (f; magni-
fication, 80) also reveals more pronounced expression of mac-3  macro-
phages than the wild-type control (e; magnification, 80). (C) Similar
MOG p35–55–specific T cell responses in p55 NS/ NS and p55 /  mice. T
cell priming was measured in LN cells isolated from C57BL/6 p55 NS/ NS
and age-matched C57BL/6 control mice (7–11 wk of age) 9 d after im-
munization with MOG peptide as described in Materials and Methods.
MOG-specific memory responses were examined in total spleen cells of
C57BL/6 p55 NS/ NS and age-matched C57BL/6 controls 20 d after EAE
induction. Proliferation was determined by [3H]thymidine incorporation
in T cell proliferation assays in which T cells were incubated with the indi-
cated concentrations of MOG peptide. For each curve, two to three mice
of each genotype were pooled together. One representative set of experi-
ments out of three performed is shown.Xanthoulea et al. 375
defense mechanisms controlled by TNF. On the other
hand,  p55 NS  mice are more susceptible to acute and
chronic inflammatory diseases. Impaired shedding of the
p55TNFR sensitizes mice to the toxicity of LPS by trans-
forming an otherwise TNF-independent and sublethal chal-
lenge to a TNF-dependent lethal endotoxic shock reaction.
Therefore, conceivably, reduced shedding of p55TNFR in
humans could lead to an increased susceptibility to inflam-
matory complications including acute septic shock and se-
vere sepsis. The lack of p55TNFR shedding in the p55 NS
model also led to exacerbated clinical outcome in two mod-
els of chronic inflammatory diseases. The expression of
nonsheddable p55TNFR led to aggravated disease in a ge-
netic model of TNF-dependent arthritis and to increased
incidence and more severe clinical course of autoimmune
demyelination in EAE. Although the detailed mechanisms
underlying these exacerbations remain to be studied, it
might be predicted that cellular hyperactivation due to sus-
tained expression of the p55TNFR on the cell surface, cou-
pled with enhanced and sustained production of TNF and
perhaps also the absence of soluble p55TNFR at the time of
response to TNF, alters the thresholds of immune activation
and tips the balance toward more aggressive inflammatory
reactions. Indirect effects of the mutation may also be at
play, potentially enhancing susceptibility to proinflamma-
tory stimuli due to an already established inflammatory state.
Taken together, our findings demonstrate that the pro-
teolytic shedding of the p55TNFR constitutes a critically
important mechanism for the regulation of TNF activity in
vivo. Although impaired receptor shedding is beneficial for
host defense to bacterial pathogens, it inevitably leads to in-
creased susceptibility to acute and chronic inflammatory
conditions. Thus, p55TNFR shedding is a mechanism that
evolved to balance the two opposing faces of TNF action.
Given the potential selective advantage that mutations af-
fecting shedding of the p55TNFR may offer to antibacterial
host defenses, it might be anticipated that such mutations
are conserved and widespread in the human population.
Therefore, assessment of TNFR shedding in humans might
be of important prognostic value for susceptibility to a vari-
ety of chronic inflammatory and autoimmune diseases.
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